BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw unusually-strong trading volume on Thursday . Approximately 139,842 shares changed hands during mid-day trading, an increase of 33% from the previous session’s volume of 105,350 shares.The stock last traded at $2.53 and had previously closed at $2.47.

Separately, Maxim Group restated a “buy” rating and issued a $5.00 target price on shares of BrainStorm Cell Therapeutics in a report on Wednesday, May 11th.

The firm’s market capitalization is $46.26 million. The stock has a 50 day moving average of $2.54 and a 200-day moving average of $2.42.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Thursday, August 11th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.13. Analysts predict that BrainStorm Cell Therapeutics Inc. will post ($0.34) EPS for the current year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.